JP2012508274A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508274A5
JP2012508274A5 JP2011536383A JP2011536383A JP2012508274A5 JP 2012508274 A5 JP2012508274 A5 JP 2012508274A5 JP 2011536383 A JP2011536383 A JP 2011536383A JP 2011536383 A JP2011536383 A JP 2011536383A JP 2012508274 A5 JP2012508274 A5 JP 2012508274A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
independently
nitrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508274A (ja
JP5432275B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063020 external-priority patent/WO2010056563A1/en
Publication of JP2012508274A publication Critical patent/JP2012508274A/ja
Publication of JP2012508274A5 publication Critical patent/JP2012508274A5/ja
Application granted granted Critical
Publication of JP5432275B2 publication Critical patent/JP5432275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536383A 2008-11-11 2009-11-03 Aktおよびp70s6キナーゼ阻害剤 Active JP5432275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
US61/113,273 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012508274A JP2012508274A (ja) 2012-04-05
JP2012508274A5 true JP2012508274A5 (enExample) 2012-07-12
JP5432275B2 JP5432275B2 (ja) 2014-03-05

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536383A Active JP5432275B2 (ja) 2008-11-11 2009-11-03 Aktおよびp70s6キナーゼ阻害剤

Country Status (36)

Country Link
US (1) US8148387B2 (enExample)
EP (1) EP2358710B1 (enExample)
JP (1) JP5432275B2 (enExample)
KR (1) KR101334460B1 (enExample)
CN (1) CN102216302B (enExample)
AR (1) AR074072A1 (enExample)
AU (1) AU2009314324B2 (enExample)
BR (1) BRPI0921916A2 (enExample)
CA (1) CA2743019C (enExample)
CO (1) CO6382114A2 (enExample)
CR (1) CR20110240A (enExample)
CY (1) CY1113409T1 (enExample)
DK (1) DK2358710T3 (enExample)
DO (1) DOP2011000129A (enExample)
EA (1) EA018947B1 (enExample)
EC (1) ECSP11011048A (enExample)
ES (1) ES2391704T3 (enExample)
HN (1) HN2011001247A (enExample)
HR (1) HRP20120738T1 (enExample)
IL (1) IL211940A (enExample)
JO (1) JO2822B1 (enExample)
MA (1) MA32776B1 (enExample)
MX (1) MX2011005000A (enExample)
MY (1) MY161461A (enExample)
NZ (1) NZ592062A (enExample)
PA (1) PA8846901A1 (enExample)
PE (1) PE20110807A1 (enExample)
PL (1) PL2358710T3 (enExample)
PT (1) PT2358710E (enExample)
RS (1) RS52520B (enExample)
SI (1) SI2358710T1 (enExample)
TN (1) TN2011000207A1 (enExample)
TW (1) TWI422587B (enExample)
UA (1) UA100190C2 (enExample)
WO (1) WO2010056563A1 (enExample)
ZA (1) ZA201102549B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2448927T3 (da) 2009-07-02 2014-06-16 Sanofi Sa Hidtil ukendte (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amidderivater, fremstilling deraf og farmaceutisk anvendelse deraf som akt-phosphoryleringshæmmere
AU2010310786B2 (en) * 2009-10-23 2014-03-27 Eli Lilly And Company AKT inhibitors
BR112013025777A2 (pt) 2011-04-07 2016-12-20 Bayer Ip Gmbh imidazopiridazinas como inibidores da quinase akt
EP2730575B1 (en) * 2011-07-09 2015-09-16 Xuanzhu Pharma Co., Ltd. Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof
PL2755965T3 (pl) 2011-09-12 2018-01-31 Merck Patent Gmbh Nowe aminy imidazolowe jako modulatory aktywności kinazowej
HRP20171655T1 (hr) 2011-09-12 2017-12-15 Merck Patent Gmbh Derivati aminopirimidina za upotrebu kao modulatori aktivnosti kinaze
CA2890288A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
JP6280130B2 (ja) 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
SG11201505999VA (en) * 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
AU2015217397B2 (en) * 2014-02-11 2019-01-17 Merck Patent Gmbh Pyrimidine imidazole amines as modulators of kinase activity
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
WO2017200087A1 (ja) * 2016-05-20 2017-11-23 大鵬薬品工業株式会社 新規5H-ピロロ[2,3-d]ピリミジン-6(7H)-オン誘導体
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3231865A1 (en) 2021-09-17 2023-03-23 Tingting SHANG Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor
TW202421127A (zh) * 2022-07-05 2024-06-01 日商大鵬藥品工業股份有限公司 5H-吡咯并〔2,3-d〕嘧啶-6(7H)-酮及其鹽體之結晶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
EP1848719B1 (en) 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Similar Documents

Publication Publication Date Title
JP2012508274A5 (enExample)
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
JP2016516043A5 (enExample)
JP2011507849A5 (enExample)
JP2010526814A5 (enExample)
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
JP2018519323A5 (enExample)
JP2009516697A5 (enExample)
JP2011512412A5 (enExample)
JP2010538076A5 (enExample)
NZ601794A (en) Di - substituted pyridine derivatives as anticancers
JP2008536825A5 (enExample)
JP2015501799A5 (enExample)
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
JP2011513305A5 (enExample)
JP2014526549A5 (enExample)
JP2011502958A5 (enExample)
JP2008520742A5 (enExample)
JP2005510473A5 (enExample)
JP2018536653A5 (enExample)
JP2013544276A5 (enExample)
JP2012530765A5 (enExample)
JP2016513681A5 (enExample)
JP2010155827A5 (enExample)